Authors

Brady Bernard, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, Oregon, United States of America.Follow
Venkatesh Rajamanickam, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, ORFollow
Christopher Dubay, Providence Cancer CenterFollow
Brian D. Piening, Molecular Genomics Laboratory, Providence Portland Medical Center, Portland, OR; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Cancer Center, Portland, OR.Follow
Emilio Alonso, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, Oregon, United States of America.Follow
Zeljka Jutric, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, Oregon, United States of America.
Ephraim Tang, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, Oregon, United States of America.
Pippa Newell, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, Oregon, United States of America.
Paul D Hansen, Providence Portland Medical Center, Portland, OR.Follow
Terry R Medler, Earle A. Chiles Research Institute, Providence Portland Medical CenterFollow
Andrew J Gunderson, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OregonFollow
Kristina H Young, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, United States of AmericaFollow
Carlo Bifulco, Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, ORFollow
Joanna Pucilowska, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, ORFollow
Marka R Crittenden, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, PortlandFollow
Michael J. Gough, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, PortlandFollow

Document Type

Article

Publication Date

1-1-2020

Publication Title

PLoS One

Keywords

Adenocarcinoma; Adult; Aged; Aged, 80 and over; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; T-Lymphocytes; Tumor Microenvironment

Abstract

Pancreatic adenocarcinoma is characterized by a complex tumor environment with a wide diversity of infiltrating stromal and immune cell types that impact the tumor response to conventional treatments. However, even in this poorly responsive tumor the extent of T cell infiltration as determined by quantitative immunohistology is a candidate prognostic factor for patient outcome. As such, even more comprehensive immunophenotyping of the tumor environment, such as immune cell type deconvolution via inference models based on gene expression profiling, holds significant promise. We hypothesized that RNA-Seq can provide a comprehensive alternative to quantitative immunohistology for immunophenotyping pancreatic cancer. We performed RNA-Seq on a prospective cohort of pancreatic tumor specimens and compared multiple approaches for gene expression-based immunophenotyping analysis compared to quantitative immunohistology. Our analyses demonstrated that while gene expression analyses provide additional information on the complexity of the tumor immune environment, they are limited in sensitivity by the low overall immune infiltrate in pancreatic cancer. As an alternative approach, we identified a set of genes that were enriched in highly T cell infiltrated pancreatic tumors, and demonstrate that these can identify patients with improved outcome in a reference population. These data demonstrate that the poor immune infiltrate in pancreatic cancer can present problems for analyses that use gene expression-based tools; however, there remains enormous potential in using these approaches to understand the relationships between diverse patterns of infiltrating cells and their impact on patient treatment outcomes.

Clinical Institute

Cancer

Department

Oncology

Department

Earle A. Chiles Research Institute

Included in

Oncology Commons

Share

COinS